| Combined cis-platinum plus radiation antitumor activity in locoregionally advanced squamous cell esophageal cancer. | |
| | |
MedLine Citation:
|
PMID: 2455256 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The synergistic activity we have observed in vitro in V-79 hamster lung cells after treatment with cis-platinum combined with irradiation, stimulated a pilot study of 31 patients with inoperable locoregionally advanced squamous cell esophageal cancer. The 27 evaluable cases (22 men and 5 women--mean age 59 years) had undergone no prior radiation or cytostatic drug therapy. Histological evidence of the tumor (26 squamous cell, 1 adenocarcinoma) was obtained by endoscopy in all patients before treatment began. The patients were irradiated in two opposite thoracic fields with a total dosage of 3,000-4,000 cGy (200 cGy daily, 1,000 weekly) concurrently with 2 cycles of cis-platinum in the dosage of 30 mg/m2 iv. daily X 4 (120 mg/m2 per cycle). The results showed that cis-platinum combined with radiation showed an evident antitumor activity which included 4 complete clinical remissions and 11 partial remissions with a response rate of 56% (15/27). In two complete responders even a pathologic remission was evident (biopsy specimen) and they are now 16+ and 18+ months free of the disease. The median remission duration has been 8+ months (14+ months in complete responders) and the median survival period for the entire group is 10+ months (for responders 15+ months, p less than 0.05). Toxicity was moderate and reversible, and mainly accounted for radiation mucositis, retrosternal pain and vomiting. A mild bone marrow suppression was observed. In 2 cases esophagotracheal fistulae occurred. The results of this study show that the combination of cis-platinum and radiation might constitute successful palliative or neoadjuvant treatment for squamous cell esophageal cancer. |
| | |
Authors:
|
K Kolarić; B Nagy; A Roth; D Zupanc; J Luetić; Z Tometić |
Related Documents
:
|
9402166 - Four-step high-dose sequential chemotherapy with hematopoietic progenitor-cell support ... 10886206 - Ccnu (lomustine), idarubicin and dexamethasone (cidex): an effective oral regimen for t... 9538146 - Neoadjuvant chemotherapy with accelerated cnf plus g-csf in patients with breast cancer... 14531496 - A pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional p... 9451426 - Impact of clinical and morphological variables in classification and regression tree-ba... 6978226 - Patterns of relapse following radiotherapy for hodgkin's disease. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Oncology Volume: 45 ISSN: 0030-2414 ISO Abbreviation: Oncology Publication Date: 1988 |
Date Detail:
|
Created Date: 1988-08-01 Completed Date: 1988-08-01 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0135054 Medline TA: Oncology Country: SWITZERLAND |
Other Details:
|
Languages: eng Pagination: 276-80 Citation Subset: IM |
Affiliation:
|
Department of Medical Oncology, Central Institute for Tumors and Allied Diseases, Zagreb, Yugoslavia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Carcinoma, Squamous Cell
/
drug therapy*,
radiotherapy Cisplatin / adverse effects, therapeutic use* Combined Modality Therapy Esophageal Neoplasms / drug therapy*, radiotherapy Female Humans Male Middle Aged Palliative Care |
| Chemical | |
Reg. No./Substance:
|
15663-27-1/Cisplatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Galanin impairs acquisition but not retrieval of spatial memory in rats studied in the Morris swim m...
Next Document: Correlation between ERICA and DCC assay in hormone receptor assessment of human breast cancer.